To enhance physical function of intermediate-frequency treatment instrument, separate treatment and pain threshold, and overcome adaptability to body, we analyzed FNS&SCS (fastigial nucleus stimulation and spinal cord stimulation) modules, and designed a kind of intermediate-frequency exponential pulse stimulation wave with amplitude modulated by random signal based on spectrum analysis and autocorrelation analysis. This wave can separate treatment and pain thresholds, and overcome the adaptability to body effectively.

Pancreatic cancer is one of the most common gastrointestinal malignancies,and the main unsolved obstacles,which we must figure out,are the early detection and diagnosis,and the improvement in treatments.The ceRNA (competing endogenous RNA,ceRNA) hypothesis provides significant clues and a novel direction for understanding the mechanisms of tumor occurrence and progression,microRNAs and lncRNAs (long non coding RNAs,lncRNAs) are important components in ceRNA hypothesis.Researches have discovered that both overexpression and silence of miRNAs and abnormal expression of some lncRNAs are related to the occurrence and progression of pancreatic cancer.This paper reviewed the contents and mechanisms of ceRNA hypothesis,members of ceRNA network as well as the role of ceRNAs in pancreatic neoplasms.

ObjectiveTo investigate the therapeutic effect and the mechanism of photodynamic therapy (PDT) on human pancreatic cancer xenograft in nude mice.MethodsThe animal model of human pancreatic cancer was produced by injecting human pancreatic cancer cells SW1990 into the dorsum of nude mice. After photosensitizer hematoporphyrin derivatives(HpD) was injected, the 632.8?nm He Ne laser was used to irradiate the tumor. The tumor′s volume was measured and factor Ⅷ was used for the immunohistochemical staining of the vessel change.ResultsThe tumor growth rate significantly decreased after PDT. Immunohistochemical staining showed significant vessel endothelial cell injury by PDT.ConclusionsPDT has a therapeutic effect on grafted pancreatic cancer possibly by incurring vascular injury.

Farnesoid X receptor(FXR), a member of the metabolic nuclear receptor superfamily, plays key roles in maintaining bile acid and lipid homeostasis.FXR is highly expressed in the entero-hepatic system where it transcriptionally regulates bile acid metabolism, intestinal barrier function and liver regeneration, etc.Loss or down regulation of FXR expression can lead to a lot of diseases, such as cholecystolithiasis, biliary cirrhosis,primary hepatic carcinoma, colon carcinoma, etc.Activation of FXR may protect against or provide a pharmacological target for these diseases.

Objective To summarize the diagnosis and treatment of abdominal Castleman disease.Methods The clinical data of 17 patients with abdominal Castleman disease who were admitted to Peking Union Medical College Hospital were retrospectively analysed. Eleven patients had no symptoms, two had an abdominal mass, two had oral ulcers and rash, one had edema and was short of breath and one had dull pain in the upper abdomen and vomiting. Two patients were examined by X-ray, 17 by ultrasound, and 13 by computed tomography(CT). Results Four patients were diagnosed with abdominal Castleman disease by CT preoperatively, and the remaining 13 patients were not conclusively diagnosed. Localized lesions of 14 patients were completely resected,and three patients with multicentric lessions received partial resection or biopsy. The diagnosis of all patients was confirmed by histopathological examination. The expression of CD3, CD20, CD21 and CD34 of 14 patients with hyaline-vascular type was positive, and the expression of CD3, CD68 and PCNA of three patients with plasma-cell type was positive. One patients was lost of follow up, and the remaining 16 patients were followed up for 3-12 months, and neither metastasis nor recurrence was observed. Conclusions The clinical manifestations of abdominal Castleman disease are nonspecific, and therefore, it is difficult to acquire a definite diagnosis before operation. Early complete resection should be applied to patients with localized Castleman disease, while for patients with multicentric Castleman disease, postoperative chemotherapy is necessary for a good prognosis.

Objective To investigate the diagnosis and treatment of mesenteric fibromatosis.Methods We analyzed retrospectively the clinical data including clinical manifestation,treatment and follow-up results of the mesenteric fibromatosis in 11 cases.ResultsNine patients presented with abdominal mass.Two cases were found during other operation occasionally.Before operation,3 cases were misdiagnosed as leiomyosarcoma,1 case as malignant neurilemmoma,1 case as lymphoma.All patients were underwent surgical resection,and were diagnosed as mesenteric fibromatosis by pathology.Following-up,from 7 months to 72 months,2 cases relapsed.Conclusions The clinical feature of mesenteric fibromatosis is nonspecific.It is difficult to make correct diagnosis preoperatively.Surgical resection is the first choice for cure of patients with mesenteric fibromatosis.

Pancreatic cancer is an aggressive malignant gastrointestinal tumor,surgical resection offers the only chance of cure. Due to its anatomic and biological characters,early stage pancreatic cancer is usually clinically silent,80％-85％ of patients present with advanced unresectable disease. Furthermore,pancreatic cancer responds poorly to most radiochemotherapeutic agents.In this article,we discuss some clinical aspects including early diagnosis,preoperative systemic assessment,surgery and perioperartive adjuvant therapy,and we hope to find the challenges as well as strategies for pancreatic cancer in order to further improve the current level of diagnosis and treatment in China.

Pancreatic neuroendocrine tumors(pNETs)have a low prevalence,and may be func-tional as secreting biologically active substance or nonfunctional. With the increased understanding of this disease,new technologies are being developed for diagnosis and treatment. However,surgical excision re-mains the primary therapy for localized tumors and the cure rate is not ideal yet. In choosing the appropri-ate therapy for locally advanced/ metastatic pNETs,medical management strategy should be made in a multidisciplinary context. In addition to chemotherapy,there have been significant advances in targeted mo-lecular therapy.

Pancreatic cancer is a highly malignant tumor,the incidence is increasing year by year globally.Due to concealed pathogenesis of which and rapid progress,only 25％ of the patients could receive operation.Adjuvant therapy has become the important methods of improving the prognosis of patients with pancreatic cancer,including chemotherapy and radiotherapy.In recent years,some prospective clinical trials have promoted the development of the adjuvant therapy.New controversy and consensus appear in the treatment of pancreatic cancer.This article reviewed the progress of chemotherapy and radiotherapy for pancreatic cancer based on adjuvant therapy and neo-adjuvant therapy for unresectable metastatic pancreatic cancer and locally advanced pancreatic cancer.

The special anatomy around the head of pancreas leads to difficulties in arriving at a definitive diagnosis for a pancreatic head mass,the management of which has recently become a hot topic and a challenge for clinicians.Despite recent advances in tumor markers,ultrasound,CT,PET/CT and MRI,some of these pancreatic head masses cannot be diagnosed with certainty.A fine needle aspiration biopsy can be used before operation; however,false negative results not infrequently happen.Based on the reports from domestic and foreign medical literatures published recently,this paper reviewed and discussed the proper treatment strategies when biopsy results from a pancreatic head mass turn out negative.